Table 1.
Baseline clinical characteristics of patients on treatment of vedolizumab and infliximab alone (N=156)
| Characteristic | Vedolizumab n=62 | Infliximab n=94 | P value |
| Median age at IMDC, years (IQR), n=156 | 63 (49–71) | 65 (50–73) | 0.634 |
| Male sex, no (%) | 41 (66) | 58 (62) | 0.358 |
| White race, no (%) | 58 (94) | 86 (91) | 0.736 |
| Median Charlson Comorbidity Index at colitis diagnosis, points (IQR), n=156 | 8 (7–9) | 8 (6–9) | 0.931 |
| Cancer type, no (%) | <0.001 | ||
| Melanoma | 10 (16) | 44 (47) | |
| Genitourinary cancer | 23 (37) | 26 (28) | |
| Lung cancer | 10 (16) | 16 (17) | |
| Others | 19 (31) | 8 (8) | |
| Cancer stage, no (%) | 0.245 | ||
| Stage III | 12 (19) | 14 (15) | |
| Stage IV | 50 (81) | 80 (85) | |
| Checkpoint inhibitor type, no. (%) | 0.041 | ||
| Anti-CTLA-4 | 6 (10) | 17 (18) | |
| Anti-PD-(L)1 | 38 (61) | 40 (43) | |
| Combination | 18 (29) | 37 (39) | |
| Median follow-up duration, months (IQR), n=156 | 15 (11–26) | 14 (7–30) | 0.542 |
CTLA-4, cytotoxic T-lymphocyte-associated protein 4; IMDC, immune-mediated diarrhea and colitis; PD-(L)-1, programmed cell death 1 protein/ligand.